Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(2023) In Brain Communications 5(2).- Abstract
The extent to which newly developed blood-based biomarkers could reduce screening costs in secondary prevention trials of Alzheimer's disease is mostly unexplored. We collected plasma amyloid-β42/40, apolipoprotein E ϵ4 status and amyloid PET at baseline in 181 cognitively unimpaired participants [the age of 72.9 (5.3) years; 61.9% female; education of 11.9 (3.4) years] from the Swedish BioFINDER-1 study. We tested whether a model predicting amyloid PET status from plasma amyloid-β42/40, apolipoprotein E status and age (combined) reduced cost of recruiting amyloid PET + cognitively unimpaired participants into a theoretical trial. We found that the percentage of cognitively unimpaired participants with an amyloid PET + scan rose from... (More)
The extent to which newly developed blood-based biomarkers could reduce screening costs in secondary prevention trials of Alzheimer's disease is mostly unexplored. We collected plasma amyloid-β42/40, apolipoprotein E ϵ4 status and amyloid PET at baseline in 181 cognitively unimpaired participants [the age of 72.9 (5.3) years; 61.9% female; education of 11.9 (3.4) years] from the Swedish BioFINDER-1 study. We tested whether a model predicting amyloid PET status from plasma amyloid-β42/40, apolipoprotein E status and age (combined) reduced cost of recruiting amyloid PET + cognitively unimpaired participants into a theoretical trial. We found that the percentage of cognitively unimpaired participants with an amyloid PET + scan rose from 29% in an unscreened population to 64% [(49, 79); P < 0.0001] when using the biomarker model to screen for high risk for amyloid PET + status. In simulations, plasma screening also resulted in a 54% reduction of the total number of amyloid PET scans required and reduced total recruitment costs by 43% [(31, 56), P < 0.001] compared to no pre-screening when assuming a 16× PET-to-plasma cost ratio. Total savings remained significant when the PET-to-plasma cost ratio was assumed to be 8× or 4×. This suggests that a simple plasma biomarker model could lower recruitment costs in Alzheimer's trials requiring amyloid PET positivity for inclusion.
(Less)
- author
- Cullen, Nicholas C. LU ; Janelidze, Shorena LU ; Stomrud, Erik LU ; Bateman, Randall J. ; Palmqvist, Sebastian LU ; Hansson, Oskar LU and Mattsson-Carlgren, Niklas LU
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, amyloid, clinical trials, PET, plasma biomarkers
- in
- Brain Communications
- volume
- 5
- issue
- 2
- article number
- fcad015
- publisher
- Oxford University Press
- external identifiers
-
- pmid:36926368
- scopus:85153337370
- ISSN
- 2632-1297
- DOI
- 10.1093/braincomms/fcad015
- language
- English
- LU publication?
- yes
- id
- 77e3c2a3-06e7-40b0-867b-45bd80980e09
- date added to LUP
- 2023-07-17 14:54:13
- date last changed
- 2024-04-19 23:36:27
@article{77e3c2a3-06e7-40b0-867b-45bd80980e09, abstract = {{<p>The extent to which newly developed blood-based biomarkers could reduce screening costs in secondary prevention trials of Alzheimer's disease is mostly unexplored. We collected plasma amyloid-β42/40, apolipoprotein E ϵ4 status and amyloid PET at baseline in 181 cognitively unimpaired participants [the age of 72.9 (5.3) years; 61.9% female; education of 11.9 (3.4) years] from the Swedish BioFINDER-1 study. We tested whether a model predicting amyloid PET status from plasma amyloid-β42/40, apolipoprotein E status and age (combined) reduced cost of recruiting amyloid PET + cognitively unimpaired participants into a theoretical trial. We found that the percentage of cognitively unimpaired participants with an amyloid PET + scan rose from 29% in an unscreened population to 64% [(49, 79); P < 0.0001] when using the biomarker model to screen for high risk for amyloid PET + status. In simulations, plasma screening also resulted in a 54% reduction of the total number of amyloid PET scans required and reduced total recruitment costs by 43% [(31, 56), P < 0.001] compared to no pre-screening when assuming a 16× PET-to-plasma cost ratio. Total savings remained significant when the PET-to-plasma cost ratio was assumed to be 8× or 4×. This suggests that a simple plasma biomarker model could lower recruitment costs in Alzheimer's trials requiring amyloid PET positivity for inclusion.</p>}}, author = {{Cullen, Nicholas C. and Janelidze, Shorena and Stomrud, Erik and Bateman, Randall J. and Palmqvist, Sebastian and Hansson, Oskar and Mattsson-Carlgren, Niklas}}, issn = {{2632-1297}}, keywords = {{Alzheimer's disease; amyloid; clinical trials; PET; plasma biomarkers}}, language = {{eng}}, number = {{2}}, publisher = {{Oxford University Press}}, series = {{Brain Communications}}, title = {{Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease}}, url = {{http://dx.doi.org/10.1093/braincomms/fcad015}}, doi = {{10.1093/braincomms/fcad015}}, volume = {{5}}, year = {{2023}}, }